WESTBOROUGH, MA, August 15, 2005- Applix, Inc. (Nasdaq: APLX), a global provider of single platform solutions for Business Performance Management (BPM) and Business Intelligence (BI), today announced its customer, GTC Biotherapeutics, Inc. (Nasdaq: GTCB, "GTC") received Start Magazine's 2005 Technology & Business Award. GTC's application, based on Applix's TM1® BPM suite for traditional Finance department applications such as budgeting, planning and forecasting helps GTC manage programs aimed at commercializing therapeutic proteins. Annually, Start Magazine award recipients are selected based on their ability to leverage technology to achieve specific, demonstrable business goals.

"We are seeing more and more of our customers expanding their use of analytics into operations, marketing, sales, management and other departments," said David Menninger, vice president of worldwide marketing and product management, Applix, Inc. "GTC's Start Magazine award not only reflects the bottom-line value many of our customers realize from their use of TM1 but also demonstrates the myriad uses of the BPM suite outside Finance for critical operations management."

"GTC relies on TM1 to plan, budget, perform activity-based costing (ABC), determine variances, and to execute Sarbanes-Oxley compliance activities," said James Kneece, senior director, Finance and Planning, GTC Biotherapeutics. "GTC required forecasting and predictive costing, actual effort and cost tracking, and total company financial reporting and analysis to manage profit and cash flow objectives. Faced with increased requirements to comply with Sarbanes-Oxley regulations, GTC needed an efficient and integrated single source of management information. TM1, Applix's single platform for business performance management, offered flexibility and customization with out-of-the-box components for rapid deployment and return on investment in meeting this objective."

"Every year Start Magazine's Technology & Business Awards showcase the manufacturing industry's best and brightest," said John Buell, editor-in-chief of Start. "The 2005 Start Magazine award recipients were selected based on their ability to leverage technology to achieve specific, quantifiable business goals. Case studies from innovative companies like GTC Biotherapeutics demonstrate how a successful manufacturing company can prosper in today's fast-moving economy. GTC has clearly demonstrated how their commitment and understanding of technology has helped the company's management team optimize corporate performance." Start Magazine focuses on the greater business issues that can be solved for manufacturing executives. Top executives have come to rely on Start for sound technological advice coupled with solid coverage of the financial, political, and management.

GTC also integrates product development activities, both for its own and its partnered programs, with its overall financial management. TM1-based applications integrate activities and costs. GTC needed a more controlled and transparent approach to project timing, determining direct, labor and overhead costs and the overall success of a given project, eliminating the traditional "guesstimate" approach. TM1's ability to access and calculate real-time information from Enterprise Resource Planning (ERP) applications, General Ledger (GL) systems, desktop applications, and other core technologies, enables GTC to create both production and ad hoc reports for the 'management' portion of BPM.

GTC designed multidimensional cubes of data to reflect its customized business model with guidance from Applix Solution Partner Creeth Richman & Associates.

Additional information on GTC's application can be found at www.applix.com/SOXwebinar.

About GTC GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATryn®, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn® in patients with a hereditary antithrombin deficiency. In addition to the ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, http://www.gtc-bio.com.

About Applix, Inc.

Applix (NASDAQ: APLX) is a global provider of Business Performance Management and Business Intelligence solutions. These solutions, based on Applix's TM1 analytics platform, enable the continuous planning, management and monitoring of performance across the financial and operational functions within the enterprise. Applix is a founder of the BPM Standards Group, and has been recognized by numerous industry analyst groups for its technical leadership and vision in the marketplace.

More than 2,000 customers worldwide use TM1 for tight integration with Excel, real-time response, adaptability, and low total cost of ownership. Delivered by Applix and by a global network of partners, TM1-based solutions help customers manage their business performance and respond to the marketplace in real time. Headquartered in Westborough, MA, Applix maintains offices in four countries in Europe, North America and the Pacific Rim. For more information about Applix, please visit www.applix.com.

Notes to Investors:

This news release contains forward-looking statements that involve risks and uncertainties. Forward-looking statements in this document are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements concerning future plans or results are only estimates and actual results could differ materially from expectations. Certain factors that could cause or contribute to such differences include without limitation, competitive pressures, changes in customer demands, adverse economic conditions, loss of key personnel, litigation, potential fluctuations in quarterly results, lengthy sales cycles, market acceptance of new or enhanced products and services, factors affecting spending by customers and other risks, uncertainties and factors including those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2004 under the heading "Risk Factors" and its most recent Quarterly Report on Form 10-Q under the heading “Factors That May Affect Future Results.” The forward-looking statements provided by the Company in this press release represent the Company's views as of the date of this release. The Company anticipates that subsequent events and developments may cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, and these forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.

©2005 Applix, Inc. All rights reserved. Applix and TM1 are registered trademarks of Applix, Inc. All other trademarks and company names mentioned are the property of their respective owners.

Contact Information: Charlotte Locke
Director, Corporate Marketing
Applix, Inc.
508-475-2441
clocke@applix.com